Webinar replay

Biopharma Dealmaking in 2023. Perspective and Projections​

Deal flow decreased, average deal values dropped, and headline grabbing M&As slowed to a trickle. Inflation soared, IPOs cratered, and SPAC just might be the new four-letter-word. After a year where the global economy slowed and uncertainty reigned, what does 2023 hold for the biopharma industry?​

Chris Dokomajilar, Founder and CEO at Dealforma, returns to Inova to offer his third annual review of the year in life science partnering. He’ll unlock all the trends in the dealmaking data and draw on his deep industry expertise to project what we’re likely to see in the biopharma dealmaking in 2023.​

Watch the replay to learn:​

  • Why large pharma merger activity slowed​
  • Where VC investments flowed, and why
  • How and where pre-clinical biotechs raised capital​
  • Whether licensing upfronts will bounce back in the new year​
Watch this replay to get expert insights from our panelist:
Chris Dokomajilar
Chris Dokomajilar
Founder and CEO
DealForma

Please complete the form below

All fields marked with a * are required.
By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.

Resources you may be interested in

samson-ZGjbiukp_-A-unsplash

Partner of Choice. By Choice

Watch webinar replay
AdobeStock_222932981 (1)-min

Biopharma Dealmaking in 2022: Trends & Forecasts

Download whitepaper
background-3

Biopharma Dealmaking in 2021: Trends and Transformation

Watch webinar replay

About Inova

Inova accelerates partnering for the future of medicine. Our cloud-based solutions help life science companies manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and innovative biotechs already use Inova.